查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1541267

2024-2032 年经前症候群治疗市场报告（按药物类型、类型、配销通路和地区）

Premenstrual Syndrome Treatment Market Report by Drug Type, Type, Distribution Channel, and Region 2024-2032
出版日期: | 出版商: IMARC | 英文 149 Pages | 商品交期: 2-3个工作天内

价格

2023年，IMARC Group经前症候群治疗市场规模达13.97亿美元。该市场的推动因素包括对精准医疗的日益关注，因为它可以提高患者的治疗效果和治疗效率，医疗保健支出的增加可以改善获得护理的机会并扩大治疗选择，以及提高女性劳动力的参与度。

经前症候群治疗市场分析：

主要市场驱动因素：对精准医疗的需求不断增长，加上医疗保健支出不断增加，正在对市场产生正面影响。

主要市场趋势：女性劳动参与度的提高和持续的技术进步正在刺激市场的成长。

地理趋势：由于其强大的医疗基础设施和强劲的经济，北美占据了最大的市场，从而提高了药物的负担能力。

竞争格局：经前症候群治疗产业的一些主要市场参与者包括艾伯维公司、巴斯夫公司、拜耳公司、雷迪博士实验室有限公司、礼来公司、葛兰素史克公司、灵北公司、辉瑞公司.、盐野义工业株式会社等。

挑战与机会：虽然市场面临对经前症候群缺乏认识和理解等挑战，但它也遇到了开发新治疗方案的机会。

经前症候群治疗市场趋势：

精准医疗日益受到关注

根据 IMARC 集团的报告，2023 年全球精准医疗市场规模将达到 752 亿美元。在经前症候群的背景下，个体之间的症状和严重程度可能存在很大差异，个人化的方法可以实现更有针对性和更有效的治疗。此外，与经前症候群相关的遗传因素或生物标记有助于为每位患者制定最有效的治疗方案。这可以改善治疗结果并减少治疗选择中的反覆试验。除此之外，透过根据患者的遗传或生理特征匹配治疗来选择不太可能引起不良反应的药物正在扩大市场成长。

医疗保健支出不断增加

随着医疗支出的增加，越来越多的人，包括受经前症候群困扰的女性，能够寻求医疗协助，包括初级保健医生、妇科医生和其他可以适当诊断和治疗经前症候群的从业人员。此外，高医疗保健支出通常与其他更容易获得经前症候群的治疗选择有关，其中包括荷尔蒙疗法、抗忧郁药物等药物治疗，以及认知行为疗法或生活方式改变等非药物治疗。高医疗保健支出为研发活动创造了更多机会，有助于找到更好的经前症候群疗法。根据医疗保险和医疗补助服务中心网站2024年更新的内容，医疗保健支出占GDP的比重预计将从2022年的17.3%增长到2032年的19.7%。

提高女性劳动参与度

根据世界银行的数据，2023 年全球女性劳动参与率为 49%。由于其症状，这对工作效率、出勤率和表现构成威胁。在意识到这些影响后，雇主和医疗保健提供者更有动力寻找有效的治疗方法，以帮助减少经前症候群造成的工作场所干扰。此外，该公司正在投资工作场所健康计划，其中包括对经前症候群等生殖健康问题的支持。这些计划提供治疗方法、围绕症状的灵活安排以及教育资源，所有这些都提高了对现有 PMS 治疗方法的认识和使用。

经前症候群治疗市场区隔：

IMARC Group提供了每个细分市场的主要趋势分析，以及 2024-2032 年全球、区域和国家层面的预测。我们的报告根据药物类型、类型和配销通路对市场进行了分类。

按药物类型细分：

止痛药

抗忧郁药

口服避孕药和卵巢抑制剂

其他的

镇痛药占大部分市场份额

该报告根据药物类型对市场进行了详细的细分和分析。这包括止痛药、抗忧郁药、口服避孕药和卵巢抑制剂等。根据该报告，镇痛药占最大的部分。

经前症候群是指在月经週期之前影响许多女性的几种生理和心理症状，例如腹痛、头痛和肌肉疼痛。止痛药受到广泛青睐，因为它们可以快速缓解这些症状，使其成为许多希望在月经週期中立即感到舒适的女性的首选。此外，人们开始意识到止痛药在控制疼痛方面的功效，这推动了经前症候群治疗市场对止痛药的需求。

按类型划分：

处方

在柜檯

场外交易占据产业最大份额

报告还提供了基于类型的详细市场细分和分析。这包括处方药和非处方药。报告称，场外交易占据最大的市场份额。

用于治疗经前症候群的非处方 (OTC) 产品包括止痛药、利尿剂和其他补充剂，如钙和镁，无需医生处方即可在柜檯购买。这种可及性使女性能够独立治疗症状，而无需去看医生。腹胀、痉挛、疲劳和情绪波动正成为经前症候群所导致的严重问题。非处方药根据不同的症状为这些问题提供了多种解决方案。非处方药品牌的知名度以及从药局、零售店和线上平台购买这些产品的便利性正在促进市场的成长。

按配销通路划分：

医院药房

药局和零售药局

网上商店

药局和零售药局是主要的细分市场

该报告根据配销通路对市场进行了详细的细分和分析。这包括医院药房、药局和零售药房以及网上商店。根据该报告，药局和零售药局是最大的细分市场。

女性更喜欢药局和药房，因为她们可以买到各种非处方药和补充剂来缓解经前症候群症状。这确保了那些患有经前症候群的女性能够以最快的方式得到缓解，而无需处方。 。其次，药局和零售药局为顾客提供多种品牌和形式的产品，可以帮助顾客根据自己的需求和症状选择所需的产品。这种多样性提高了个人满意度，并确保人们可以找到根据其特定需求量身定制的产品。

按地区划分：

北美洲

美国

加拿大

亚太

中国

日本

印度

韩国

澳洲

印尼

其他的

欧洲

德国

法国

英国

义大利

西班牙

俄罗斯

其他的

拉丁美洲

巴西

墨西哥

其他的

中东和非洲

北美市场领先，占据最大的经前症候群治疗市场份额

该报告还对所有主要区域市场进行了全面分析，其中包括北美（美国和加拿大）；亚太地区（中国、日本、印度、韩国、澳洲、印尼等）；欧洲（德国、法国、英国、义大利、西班牙、俄罗斯等）；拉丁美洲（巴西、墨西哥等）；以及中东和非洲。报告称，北美是经前症候群治疗的最大区域市场。

加拿大健康资讯研究所网站上发表的一篇文章显示，2023年加拿大医疗保健支出将达到3,440亿加币。女性，包括经前症候群。这包括改善获得能够有效诊断和治疗经前症候群的医疗保健专业人员的机会，从而提高患者对该疾病的认识和认识。此外，北美的经前症候群发生率很高，这促使对有效治疗解决方案的巨大需求。此外，该地区经济强劲，导致医疗保健服务和药物的负担能力提高，进一步推动市场成长。

竞争格局：

市场研究报告也对市场竞争格局进行了全面分析。也提供了所有主要公司的详细资料。经前症候群治疗产业的一些主要市场参与者包括艾伯维公司、巴斯夫公司、拜耳公司、雷迪博士实验室有限公司、礼来公司、葛兰素史克公司、灵北公司、辉瑞公司和盐野义公司有限公司

（请注意，这只是关键参与者的部分列表，报告中提供了完整列表。）

主要参与者正在开发和引入新的药物和治疗方法来管理经前症候群症状，扩大患者的治疗选择。他们正在进行研究并参与临床试验，以便更好地了解经前症候群机制、验证治疗效果并探索新的治疗方法。此外，许多公司都专注于个人化医疗方法，根据患者个别特征客製化治疗方案，改善治疗结果和患者满意度。主要参与者参与宣传工作，以提高对经前症候群的认识，提高诊断率，并向医疗保健提供者和患者提供有关可用治疗方案的教育。他们专注于整合数位健康技术，例如症状追踪应用程式、穿戴式装置和远距医疗解决方案，以提高患者护理和治疗效果。例如，2024 年，Samphire Neuroscience 新创公司筹集了 230 万美元，利用神经科技穿戴装置解决经前症候群和经期疼痛。

经前症候群治疗市场新闻：

2023 年 9 月 12 日：后期临床阶段生物製药公司 Vistagen 宣布 PH80 探索性 2A 期研究取得正面结果，该研究用于急性管理经前烦躁障碍 (PMDD) 症状，包括负面情绪以及身体和行为症状。

本报告回答的关键问题

  • 2023年全球经前症候群治疗市场规模是多少
  • 2024-2032年全球经前症候群治疗市场的预期成长率是多少
  • 推动全球经前症候群治疗市场的关键因素是什么
  • COVID-19 对全球经前症候群治疗市场有何影响
  • 根据药物类型，全球经前症候群治疗市场的细分情况如何
  • 全球经前症候群治疗市场按类型划分是怎样的
  • 基于配销通路的全球经前症候群治疗市场的细分是什么
  • 全球经前症候群治疗市场的重点区域有哪些
  • 谁是全球经前症候群治疗市场的主要参与者/公司

本报告回答的关键问题

  • 2023年全球经前症候群治疗市场规模有多大？ 2024-2032年全球经前症候群治疗市场的预期成长率是多少？
  • 推动全球经前症候群治疗市场的关键因素是什么？
  • COVID-19 对全球经前症候群治疗市场有何影响？
  • 根据药物类型，全球经前症候群治疗市场的细分情况如何？
  • 全球经前症候群治疗市场按类型划分是怎样的？
  • 基于配销通路的全球经前症候群治疗市场的细分情况如何？
  • 全球经前症候群治疗市场的关键地区有哪些？
  • 全球经前症候群治疗市场的主要参与者/公司有哪些？

目录

第一章：前言

第 2 章：范围与方法

  • 研究目的
  • 利害关係人
  • 数据来源
    • 主要来源
    • 二手资料
  • 市场预测
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第 3 章：执行摘要

第 4 章：简介

  • 概述
  • 主要行业趋势

第 5 章：全球经前症候群治疗市场

  • 市场概况
  • 市场表现
  • COVID-19 的影响
  • 市场预测

第 6 章：市场区隔：依药物类型

  • 止痛药
    • 市场趋势
    • 市场预测
  • 抗忧郁药
    • 市场趋势
    • 市场预测
  • 口服避孕药和卵巢抑制剂
    • 市场趋势
    • 市场预测
  • 其他的
    • 市场趋势
    • 市场预测

第 7 章：市场区隔：按类型

  • 处方
    • 市场趋势
    • 市场预测
  • 在柜檯
    • 市场趋势
    • 市场预测

第 8 章：市场区隔：按配销通路

  • 医院药房
    • 市场趋势
    • 市场预测
  • 药局和零售药局
    • 市场趋势
    • 市场预测
  • 网上商店
    • 市场趋势
    • 市场预测

第 9 章：市场区隔：按地区

  • 北美洲
    • 美国
    • 加拿大
  • 亚太
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 俄罗斯
    • 其他的
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他的
  • 中东和非洲
    • 市场趋势
    • 市场细分：按国家/地区
    • 市场预测

第 10 章：SWOT 分析

  • 概述
  • 优势
  • 弱点
  • 机会
  • 威胁

第 11 章：价值链分析

第 12 章：波特五力分析

  • 概述
  • 买家的议价能力
  • 供应商的议价能力
  • 竞争程度
  • 新进入者的威胁
  • 替代品的威胁

第 13 章：价格分析

第14章：竞争格局

  • 市场结构
  • 关键参与者
  • 关键参与者简介
    • AbbVie Inc.
    • BASF SE
    • Bayer AG
    • Dr. Reddy's Laboratories Ltd
    • Eli Lilly and Company
    • GlaxoSmithKline Plc.
    • H. Lundbeck A/S
    • Pfizer Inc.
    • SHIONOGI & Co. Ltd.
Product Code: SR112024A4284

The global premenstrual syndrome treatment market size reached US$ 1,397.0 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 1,890.8 Million by 2032, exhibiting a growth rate (CAGR) of 3.3% during 2024-2032. The market is driven by the growing focus on precision medicine, as it enhances patient outcomes and treatment efficiency, rising healthcare spending, which improves access to care and expands treatment options, and increasing female workforce participation.

Premenstrual Syndrome Treatment Market Analysis:

Major Market Drivers: The growing demand for precision medicine, along with the rising healthcare expenditure, is positively influencing the market.

Key Market Trends: Increasing female workforce participation and ongoing technological advancements are stimulating the growth of the market.

Geographical Trends: North America holds the largest segment because of its strong healthcare infrastructure and robust economy, which leads to greater affordability of medications.

Competitive Landscape: Some of the major market players in the premenstrual syndrome treatment industry include AbbVie Inc., BASF SE, Bayer AG, Dr. Reddy's Laboratories Ltd, Eli Lilly and Company, GlaxoSmithKline Plc., H. Lundbeck A/S, Pfizer Inc., SHIONOGI & Co. Ltd., among many others.

Challenges and Opportunities: While the market faces challenges like lack of awareness and understanding about PMS, it also encounters opportunities in the development of new treatment options.

Premenstrual Syndrome Treatment Market Trends:

Growing focus on precision medicine

As per the IMARC Group's report, the global precision medicine market reached US$ 75.2 Billion in 2023. Precision medicine can deliver medical interventions that are tailored as per patient characteristics including genetic profile, hormone status, and symptoms. In the context of PMS, it can vary widely in terms of symptoms and severity among individuals, personalized approaches allow for more targeted and effective treatments. Furthermore, genetic factors or biomarkers that are linked to PMS help in tailoring treatment options to be most effective for each patient. This is leading to improved outcomes and lesser trial and error in treatment options. Apart from this, by selecting medications that are less likely to cause an adverse reaction by matching patients with treatments based on their genetic or physiological profiles is expanding the market growth.

Rising healthcare spending

As healthcare expenditure is increasing, more people, including women troubled with PMS, are able to seek medical help, including primary care physicians, gynecologists and other practitioners who may diagnose and treat PMS appropriately. In addition, high healthcare spending often found to be associated with higher access to other treatment options of PMS, which includes pharmacological treatment like hormonal therapies, antidepressants, and non-pharmacological therapies like cognitive behavioral therapy or lifestyle modifications. High healthcare expenditure is creating more opportunities for R&D activities that can help find better PMS therapies. According to the content updated in 2024 on the website of the Centers for Medicare & Medicaid Services, the healthcare spending share of GDP is forecasted to grow from 17.3% in 2022 to 19.7% in 2032.

Increasing female workforce participation

As per the World Bank, female labor force participation rates were 49% worldwide in 2023. As more women are entering the workforce, the economic implications of PMS are becoming more apparent. This poses a threat to productivity, attendance and performance at work due to its symptoms. Recognizing these impacts, employers and healthcare providers are more motivated to find effective treatments that can help reduce the workplace disruptions caused by PMS. In addition, companies are investing in workplace wellness programs that include support for reproductive health issues like PMS. These programs offer access to therapies, flexible scheduling around symptomatic days, and educational resources, all of which increase awareness and use of available PMS treatments.

Premenstrual Syndrome Treatment Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the global, regional, and country levels for 2024-2032. Our report has categorized the market based on drug type, type, and distribution channel.

Breakup by Drug Type:

Analgesics

Antidepressants

Oral Contraceptives and Ovarian Suppression Agents

Others

Analgesics accounts for the majority of the market share

The report has provided a detailed breakup and analysis of the market based on the drug type. This includes analgesics, antidepressants, oral contraceptives and ovarian suppression agents, and others. According to the report, analgesics represents the largest segment.

Premenstrual syndrome refers to several symptoms that are physical and psychological in nature and which affect many women prior to menstrual cycles, such as abdominal pain, headaches, and muscular pain. Analgesics are widely preferred as they provide quick relief from these symptoms, making them a go-to choose for many women looking immediate comfort during their menstrual cycles. In addition, people are getting aware about their efficiency in controlling pain, which is driving the demand for analgesics in the PMS treatment market.

Breakup by Type:

Prescription

Over-the-Counter

Over-the-counter holds the largest share of the industry

A detailed breakup and analysis of the market based on the type have also been provided in the report. This includes prescription and over-the-counter. According to the report, over-the-counter accounts for the largest market share.

Over-the-counter (OTC) products for PMS include pain relievers, diuretics, and other supplements like calcium and magnesium that one can be purchased on the counter without the prescription of doctor. This accessibility allows women treat symptoms independently without having to see a doctor. Bloating, cramping, fatigue, and mood swings are becoming serious problems as a result of PMS. OTC medicines offer numerous solutions to these issues as per different symptoms. The familiarity of OTC brands and the ease of purchasing these products from pharmacies, retail stores, and online platforms is contributing to the market growth.

Breakup by Distribution Channel:

Hospital Pharmacies

Drug Stores and Retail Pharmacies

Online Stores

Drugs stores and retail pharmacies represent the leading market segment

The report has provided a detailed breakup and analysis of the market based on the distribution channel. This includes hospital pharmacies, drug stores and retail pharmacies, and online stores. According to the report, drugs stores and retail pharmacies represent the largest segment.

Women are preferring drug stores and pharmacies as they can get a wide range of OTC medications and supplements to alleviate PMS symptoms. This ensures that those women suffering from PMS can get relief in the quickest way possible without the need for a prescription. . Secondly, drug stores and retail pharmacies offer customers a wide diversity of brands and forms of products which can help them select the required products according to their needs and symptoms. This variety enhances individual satisfaction and ensures that people can find products tailored as per their specific needs.

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

North America leads the market, accounting for the largest premenstrual syndrome treatment market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America represents the largest regional market for premenstrual syndrome treatment.

As per an article published on the website of Canadian Institute for Health Information, Canada health care spending reached $344 billion in 2023. As healthcare expenditures is rising, there is a corresponding increase in the availability of specialized healthcare services and resources dedicated to the health of women, including PMS. This includes improved access to healthcare professionals who can diagnose and treat PMS effectively, leading to greater awareness and recognition of the condition among patients. Moreover, North America has a high prevalence of PMS cases, which prompts a significant demand for effective treatment solutions. In addition, the strong economy of the region, leading to the greater affordability of healthcare services and medications, further driving the market growth.

Competitive Landscape:

The market research report has also provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the major market players in the premenstrual syndrome treatment industry include AbbVie Inc., BASF SE, Bayer AG, Dr. Reddy's Laboratories Ltd, Eli Lilly and Company, GlaxoSmithKline Plc., H. Lundbeck A/S, Pfizer Inc. and SHIONOGI & Co. Ltd.

(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)

Key players are developing and introducing new medications and treatments for managing PMS symptoms, expanding treatment choices for patients. They are conducting research and participating in clinical trials to better understand PMS mechanisms, validate treatment efficacy, and explore new therapeutic approaches. Moreover, many companies are focusing on personalized medicine approaches to tailor treatments based on individual patient characteristics, improving treatment outcomes and patient satisfaction. Key players are involved in advocacy efforts to raise awareness about PMS, improve diagnosis rates, and educate healthcare providers and patients about available treatment options. They are focusing on integrating digital health technologies, such as apps for symptom tracking, wearable devices, and telemedicine solutions, to enhance patient care and treatment outcome. For instance, in 2024, Samphire Neuroscience startup raised $2.3M to tackle PMS and period pain using neurotechnology wearable.

Premenstrual Syndrome Treatment Market News:

September 12, 2023: Vistagen, a late clinical-stage biopharmaceutical company announced positive results from exploratory phase 2A study of PH80 for acute management of the symptoms of premenstrual dysphoric disorder (PMDD), including negative mood and physical and behavioral symptoms.

Key Questions Answered in This Report

  • 1. What was the size of the global premenstrual syndrome treatment market in 2023?
  • 2. What is the expected growth rate of the global premenstrual syndrome treatment market during 2024-2032?
  • 3. What are the key factors driving the global premenstrual syndrome treatment market?
  • 4. What has been the impact of COVID-19 on the global premenstrual syndrome treatment market?
  • 5. What is the breakup of the global premenstrual syndrome treatment market based on the drug type?
  • 6. What is the breakup of the global premenstrual syndrome treatment market based on the type?
  • 7. What is the breakup of the global premenstrual syndrome treatment market based on the distribution channel?
  • 8. What are the key regions in the global premenstrual syndrome treatment market?
  • 9. Who are the key players/companies in the global premenstrual syndrome treatment market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Premenstrual Syndrome Treatment Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Drug Type

  • 6.1 Analgesics
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Antidepressants
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Oral Contraceptives and Ovarian Suppression Agents
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Others
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast

7 Market Breakup by Type

  • 7.1 Prescription
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Over-the-Counter
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast

8 Market Breakup by Distribution Channel

  • 8.1 Hospital Pharmacies
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Drug Stores and Retail Pharmacies
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Online Stores
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 AbbVie Inc.
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 BASF SE
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 Bayer AG
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 Dr. Reddy's Laboratories Ltd
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
    • 14.3.5 Eli Lilly and Company
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
      • 14.3.5.4 SWOT Analysis
    • 14.3.6 GlaxoSmithKline Plc.
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis
    • 14.3.7 H. Lundbeck A/S
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
      • 14.3.7.4 SWOT Analysis
    • 14.3.8 Pfizer Inc.
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
      • 14.3.8.4 SWOT Analysis
    • 14.3.9 SHIONOGI & Co. Ltd.
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 Financials
      • 14.3.9.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Premenstrual Syndrome Treatment Market: Major Drivers and Challenges
  • Figure 2: Global: Premenstrual Syndrome Treatment Market: Sales Value (in Million US$), 2018-2023
  • Figure 3: Global: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 4: Global: Premenstrual Syndrome Treatment Market: Breakup by Drug Type (in %), 2023
  • Figure 5: Global: Premenstrual Syndrome Treatment Market: Breakup by Type (in %), 2023
  • Figure 6: Global: Premenstrual Syndrome Treatment Market: Breakup by Distribution Channel (in %), 2023
  • Figure 7: Global: Premenstrual Syndrome Treatment Market: Breakup by Region (in %), 2023
  • Figure 8: Global: Premenstrual Syndrome Treatment (Analgesics) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 9: Global: Premenstrual Syndrome Treatment (Analgesics) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 10: Global: Premenstrual Syndrome Treatment (Antidepressants) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 11: Global: Premenstrual Syndrome Treatment (Antidepressants) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 12: Global: Premenstrual Syndrome Treatment (Oral Contraceptives and Ovarian Suppression Agents) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 13: Global: Premenstrual Syndrome Treatment (Oral Contraceptives and Ovarian Suppression Agents) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 14: Global: Premenstrual Syndrome Treatment (Other Drug Types) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 15: Global: Premenstrual Syndrome Treatment (Other Drug Types) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 16: Global: Premenstrual Syndrome Treatment (Prescription) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 17: Global: Premenstrual Syndrome Treatment (Prescription) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 18: Global: Premenstrual Syndrome Treatment (Over-the-Counter) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 19: Global: Premenstrual Syndrome Treatment (Over-the-Counter) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 20: Global: Premenstrual Syndrome Treatment (Hospital Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 21: Global: Premenstrual Syndrome Treatment (Hospital Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 22: Global: Premenstrual Syndrome Treatment (Drug Stores and Retail Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 23: Global: Premenstrual Syndrome Treatment (Drug Stores and Retail Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 24: Global: Premenstrual Syndrome Treatment (Online Stores) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 25: Global: Premenstrual Syndrome Treatment (Online Stores) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 26: North America: Premenstrual Syndrome Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 27: North America: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 28: United States: Premenstrual Syndrome Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 29: United States: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 30: Canada: Premenstrual Syndrome Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 31: Canada: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 32: Asia-Pacific: Premenstrual Syndrome Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 33: Asia-Pacific: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 34: China: Premenstrual Syndrome Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 35: China: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 36: Japan: Premenstrual Syndrome Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 37: Japan: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 38: India: Premenstrual Syndrome Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 39: India: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 40: South Korea: Premenstrual Syndrome Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 41: South Korea: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 42: Australia: Premenstrual Syndrome Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 43: Australia: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 44: Indonesia: Premenstrual Syndrome Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 45: Indonesia: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 46: Others: Premenstrual Syndrome Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 47: Others: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 48: Europe: Premenstrual Syndrome Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 49: Europe: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 50: Germany: Premenstrual Syndrome Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 51: Germany: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 52: France: Premenstrual Syndrome Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 53: France: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 54: United Kingdom: Premenstrual Syndrome Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 55: United Kingdom: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 56: Italy: Premenstrual Syndrome Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 57: Italy: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 58: Spain: Premenstrual Syndrome Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 59: Spain: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 60: Russia: Premenstrual Syndrome Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 61: Russia: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 62: Others: Premenstrual Syndrome Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 63: Others: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 64: Latin America: Premenstrual Syndrome Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 65: Latin America: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 66: Brazil: Premenstrual Syndrome Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 67: Brazil: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 68: Mexico: Premenstrual Syndrome Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 69: Mexico: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 70: Others: Premenstrual Syndrome Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 71: Others: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 72: Middle East and Africa: Premenstrual Syndrome Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 73: Middle East and Africa: Premenstrual Syndrome Treatment Market: Breakup by Country (in %), 2023
  • Figure 74: Middle East and Africa: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 75: Global: Premenstrual Syndrome Treatment Industry: SWOT Analysis
  • Figure 76: Global: Premenstrual Syndrome Treatment Industry: Value Chain Analysis
  • Figure 77: Global: Premenstrual Syndrome Treatment Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Premenstrual Syndrome Treatment Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Premenstrual Syndrome Treatment Market Forecast: Breakup by Drug Type (in Million US$), 2024-2032
  • Table 3: Global: Premenstrual Syndrome Treatment Market Forecast: Breakup by Type (in Million US$), 2024-2032
  • Table 4: Global: Premenstrual Syndrome Treatment Market Forecast: Breakup by Distribution Channel (in Million US$), 2024-2032
  • Table 5: Global: Premenstrual Syndrome Treatment Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 6: Global: Premenstrual Syndrome Treatment Market: Competitive Structure
  • Table 7: Global: Premenstrual Syndrome Treatment Market: Key Players